Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net – Burnie Online News
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Continue Reading
-
Noosa News21 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General17 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News16 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Business18 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…